The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...

Please provide your email address to receive an email when new articles are posted on . Glaukos submitted a new drug application to the FDA for Epioxa, an epithelium-on corneal cross-linking iLink ...

Market is poised for steady growth due to rising prevalence of corneal disorders, adoption of advanced therapies, and increasing awareness of ocular health. PED, a rare ocular condition, requires ...

The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...

Several studies conducted over the last decade have concluded that dry eye disease (DED) affects up to 50% of the U.S. population, creating a liability for the nation's health care system that is ...

This study identifies mechanisms of epithelial growth post-SMILE surgery and suggests preventive and treatment measures, including subflap debris removal, to address corneal epithelial ingrowth.

Also known as epithelial basement membrane dystrophy, map-dot-fingerprint dystrophy gets its name from the unusual appearance of the cornea during an eye examination.Map-dot-fingerprint dystrophy, ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Please provide your email address to receive an email when new articles are posted on . Remarkable advances have occurred in corneal surgery in the past 10 years. These advances include simpler ...

In vivo laser axotomy of a single subbasal fiber (SBF) in an adult mouse. The Ocular Neurobiology laboratory at the Institute for Neurosciences, a joint center of Miguel Hernández University (UMH) in ...